MetaVia Inc. — Director's Dealing 2017

Mar 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2017-03-10

Reporting Person: Hawryluk P. Kent (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-10	Common Stock	P	25000	$9.47	Acquired	81889	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-10	Warrant to Purchase Common Stock	$10.4	P	18750	Acquired	2022-03-15	Common Stock (18750)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	32062	Direct

Footnotes

F1: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017.

F2: These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Revocable Trust.